临床资料 1989年3月以来,原发性肝癌Ⅲ期(硬化型)病例按入院顺序交替分成两组,各为41例。治疗组男32例,女9例,年龄42～58岁。对照组男30例,女11例,年龄39～60岁。治疗组服甲氰咪胍0.2g4次/日,长期用药;对照组用中草药治疗。两组支持疗法相同,均不用化疗等其他疗法。结果观察治疗开始至临终时各组上消化道大出血发生率及存活期(附表)。此外,对照组中14例因发生严重肺感染而死亡,大出血18例有10例在1周内死亡,而治疗组无此种死亡病例。讨论甲氰咪胍是H_2受体拮抗剂,能对抗组织胺引起的胃酸分泌,从而使晚期肝癌患者脆弱的 Clinical data Since March 1989, primary liver cancer patients with stage III (sclerotic) cases were alternately divided into two groups according to the order of admission, 41 cases each. The treatment group included 32 males and 9 females, aged 42-58 years. The control group included 30 males and 11 females, aged 39 to 60 years. The treatment group was given cimetidine 0.2g 4 times/day for long-term use; the control group was treated with Chinese herbs. The two groups of supportive therapies are the same and do not use chemotherapy or other therapies. RESULTS: The incidence and survival of major gastrointestinal bleeding in each group from the start of treatment to the end of life (table). In addition, 14 patients in the control group died of severe lung infections, and 18 patients with major bleeding died in 1 week in 10 patients. There was no such death in the treatment group. Discuss that cimetidine is an H_2 receptor antagonist that fights histamine-induced gastric acid secretion, making patients with advanced liver cancer vulnerable